| Orally administered TKI with antifibrotic properties |
| Reduces lung function deterioration in patients with IPF, other chronic fibrosing ILDs with a progressive phenotype and SSc-ILD |
| Clinical benefit persists over long-term treatment |
| Manageable tolerability profile; most common adverse events are gastrointestinal |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.